{"id":"pipenzolate","rwe":[{"pmid":"25545351","year":"2015","title":"Validated green high-performance liquid chromatographic methods for the determination of coformulated pharmaceuticals: a comparison with reported conventional methods.","finding":"","journal":"Journal of separation science","studyType":"Clinical Study"},{"pmid":"15135857","year":"2004","title":"Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.","finding":"","journal":"Reproductive toxicology (Elmsford, N.Y.)","studyType":"Clinical Study"},{"pmid":"10845189","year":"2000","title":"Neonatal poisonings in middle Anatolia of Turkey: an analysis of 72 cases.","finding":"","journal":"The Journal of toxicological sciences","studyType":"Clinical Study"},{"pmid":"9410827","year":"1997","title":"Medical practitioners and their practices in acute diarrhea.","finding":"","journal":"Indian pediatrics","studyType":"Clinical Study"},{"pmid":"1346854","year":"1992","title":"Return to Pakistan of pipenzolate plus phenobarbitone.","finding":"","journal":"Lancet (London, England)","studyType":"Clinical Study"}],"tags":[{"label":"pipenzolate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03AB14","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["pipenzolate","pipenzolate bromide"],"offLabel":[],"synonyms":["pipenzolate","pipenzolate bromide"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"pipenzolate","explanation":"Think of acetylcholine like a messenger that tells muscles to contract. Pipenzolate blocks this messenger, which can help to relax muscles and reduce spasms. This can be helpful in treating conditions where muscles are overactive or spasmodic.","oneSentence":"Pipenzolate works by blocking the action of acetylcholine, a neurotransmitter that plays a key role in muscle contraction and other bodily functions.","technicalDetail":"Pipenzolate is a competitive antagonist of the muscarinic acetylcholine receptor, specifically targeting the M1 subtype. By blocking the action of acetylcholine at this receptor, pipenzolate can reduce the excitatory effects of acetylcholine on smooth muscle and glands."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2185","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PIPENZOLATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:20:41.356375","biosimilars":[],"competitors":[{"drugName":"glycopyrronium bromide","drugSlug":"glycopyrronium-bromide","fdaApproval":"1961-08-11","relationship":"same-class"},{"drugName":"oxyphenonium","drugSlug":"oxyphenonium","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"propantheline","drugSlug":"propantheline","fdaApproval":"1953-04-02","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methanthelinium","drugSlug":"methanthelinium","fdaApproval":"1951-07-03","relationship":"same-class"},{"drugName":"tridihexethyl","drugSlug":"tridihexethyl","fdaApproval":"1954-09-15","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"isopropamide","drugSlug":"isopropamide","fdaApproval":"1957-10-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hexocyclium","drugSlug":"hexocyclium","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mepenzolate","drugSlug":"mepenzolate","fdaApproval":"1956-11-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"diphemanil","drugSlug":"diphemanil","fdaApproval":"1976-05-17","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"pipenzolate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glycopyrronium-bromide","brandName":"glycopyrronium bromide","genericName":"glycopyrronium bromide","approvalYear":"1961","relationship":"same-class"},{"drugId":"oxyphenonium","brandName":"oxyphenonium","genericName":"oxyphenonium","approvalYear":"","relationship":"same-class"},{"drugId":"propantheline","brandName":"propantheline","genericName":"propantheline","approvalYear":"1953","relationship":"same-class"},{"drugId":"methanthelinium","brandName":"methanthelinium","genericName":"methanthelinium","approvalYear":"1951","relationship":"same-class"},{"drugId":"tridihexethyl","brandName":"tridihexethyl","genericName":"tridihexethyl","approvalYear":"1954","relationship":"same-class"},{"drugId":"isopropamide","brandName":"isopropamide","genericName":"isopropamide","approvalYear":"1957","relationship":"same-class"},{"drugId":"hexocyclium","brandName":"hexocyclium","genericName":"hexocyclium","approvalYear":"","relationship":"same-class"},{"drugId":"mepenzolate","brandName":"mepenzolate","genericName":"mepenzolate","approvalYear":"1956","relationship":"same-class"},{"drugId":"diphemanil","brandName":"diphemanil","genericName":"diphemanil","approvalYear":"1976","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"001742","UNII":"RS3K5YXV34","CHEBI":"CHEBI:95178","INN_ID":"652","RXNORM":"202840","UMLSCUI":"C0071103","ChEMBL_ID":"CHEMBL1393947","KEGG_DRUG":"D07084","DRUGBANK_ID":"DB13844","PUBCHEM_CID":"4832","SNOMEDCT_US":"387425004","SECONDARY_CAS_RN":"125-51-9","MESH_SUPPLEMENTAL_RECORD_UI":"C004377"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":16,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AB14","allCodes":["A03AB14","A03CA09"]},"biosimilarFilings":[],"recentPublications":[{"date":"2015 Mar","pmid":"25545351","title":"Validated green high-performance liquid chromatographic methods for the determination of coformulated pharmaceuticals: a comparison with reported conventional methods.","journal":"Journal of separation science"},{"date":"2004 Jun","pmid":"15135857","title":"Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.","journal":"Reproductive toxicology (Elmsford, N.Y.)"},{"date":"2000 May","pmid":"10845189","title":"Neonatal poisonings in middle Anatolia of Turkey: an analysis of 72 cases.","journal":"The Journal of toxicological sciences"},{"date":"1997 Jun","pmid":"9410827","title":"Medical practitioners and their practices in acute diarrhea.","journal":"Indian pediatrics"},{"date":"1992 Feb 22","pmid":"1346854","title":"Return to Pakistan of pipenzolate plus phenobarbitone.","journal":"Lancet (London, England)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"PIPENZOLATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pipenzolate is a small molecule drug in the pipenzolate class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown, and it has not been approved by the FDA for any indications. Pipenzolate's commercial status, including whether it is patented or generic, and its availability from generic manufacturers, are also unknown. As a result, its half-life, bioavailability, and key safety considerations are also unclear. Further research is needed to understand the properties and potential uses of pipenzolate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}